Invida India today announced plans to expand its dermatology portfolio in India, with the launch of Papulex for Acne management and Atopiclair for Atopic Dermatitis. The company hopes to meet the needs of the rapidly expanding skin health sector in the region. Invida India aims to address the unmet needs in many areas of skin care, including dermatology, by bringing world class medicines and treatment solutions to India.
Acne affects 80% of adolescents and 20% of adults, with more severity in men and higher levels of persistency in women. Studies show that acne triggers body image issues and low self-esteem in people and in certain cases can even lead to depression and severe anxiety. Atopic dermatitis occurs primarily in infants and children, affecting 5-15% of school children and 2-10% of adults in India. However, lack of effective options has led to chronic skin conditions in many of these patients. Invida India intends to change this by introducing vital treatment options and advanced skin health solutions to India to improve outcomes for patients in the areas of wound care, skin repair and dermatology.
Speaking on the significance of this expansion, Mr. Girdhar Balwani, Invida's Managing Director in India, says, "Invida hopes to address the gap felt by Indian patients who do not have access to the same treatment options as their Western counterparts by introducing innovative and affordable treatments. We are leveraging our expertise in the area of skin health to benefit Indian patients through the launch of Papulex oil-free cream and Atopiclair cream. This is just the beginning and it is our endeavor to continually look at opportunities that can benefit the Indian patient".
Papulex is an ideal companion for the long-term management of acne to reduce marks and prevent breakouts. Numerous studies show that people suffering from acne experience increased body image dissatisfaction, social anxiety, low self-esteem and symptoms of depression1. All the Papulex variants, including the Cleansing gel, Isocorrexion and Sunscreen, will be introduced over the next few months.
Invida will also launch its new dermatology product, Atopiclair, which results in flare-remission providing symptomatic relief and control of atopic dermatitis. Atopiclair is clinically proven to reduce itch and the need for steroids. Atopic dermatitis affects up to 20% of young children2. The Atopiclair cream launch this month will be followed by the launch of Atopiclair lotion in October 2011.
Invida was formed in 2005, by a strategic partnership between Quintiles, the world's leading pharmaceutical services organization, Temasek Holdings, one of the world's largest investment companies, and the Zuellig Group, the largest pharmaceutical distribution and supply chain management network in Asia Pacific. Invida aims to become the leading provider of important healthcare brands and services to improve the lives of people in the Asia Pacific region. Invida partners with emerging and multinational biopharmaceutical companies to commercialize differentiated products. Its unique advantage is that it offers a single point of entry into Asia Pacific at any stage of the commercial value chain from regulatory approval and product launch to lifecycle management.
/afaqs/media/member_avatars/b19bc90752f22463c21493ea40ad04dd26b32ea4045d163717734c0181e00e52.png )
Follow Us/afaqs/media/agency_attachments/2024-10-10t065829449z-afaqs_640x480.png)
/afaqs/media/post_attachments/d4d065e647ab3202096b6238246d164fb8df8eb64e2c63981cca545105068e91.jpg)